Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders
Sosei Group Corporation has translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK, and KU Leuven, Belgium. Sosei Heptares focuses on the design and development of structure-based drugs (SBDDs) focused on G-protein-coupled receptors (GPCRs). The goal of the agreements is to apply the innovative technologies and research …
Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders Read More »
